VIVUS Names New CEO; Incumbent CEO Resigns Due to Health Concerns
03. September 2013 07:00 ET
|
VIVUS, Inc.
MOUNTAIN VIEW, Calif., Sept. 3, 2013 (GLOBE NEWSWIRE) -- VIVUS, Inc. (Nasdaq:VVUS) today announced that Anthony P. Zook has resigned as Chief Executive Officer and from the VIVUS Board of Directors,...
New Review Article Discusses Treatment of the Obese Patient in Primary Care
27. August 2013 07:30 ET
|
VIVUS, Inc.
MOUNTAIN VIEW, Calif., Aug. 27, 2013 (GLOBE NEWSWIRE) -- VIVUS, Inc. (Nasdaq:VVUS) today announced that a review article has been published online in Postgraduate Medicine examining the treatment of...
VIVUS Reports Second Quarter and First Six Months 2013 Financial Results
06. August 2013 16:05 ET
|
VIVUS, Inc.
MOUNTAIN VIEW, Calif., Aug. 6, 2013 (GLOBE NEWSWIRE) -- VIVUS,Inc. (Nasdaq:VVUS) ("VIVUS"), which sells the obesity drug Qsymia® (phentermine and topiramate extended-release) capsules CIV in the...
VIVUS Announces Date of Second Quarter 2013 Financial Results and Conference Call
05. August 2013 07:30 ET
|
VIVUS, Inc.
MOUNTAIN VIEW, Calif., Aug. 5, 2013 (GLOBE NEWSWIRE) -- VIVUS, Inc. (Nasdaq:VVUS) today announced that it will report financial results for the second quarter ended June 30, 2013 after the Nasdaq...
VIVUS Announces Commercial Supply Agreement With Sanofi to Produce Avanafil
01. August 2013 07:30 ET
|
VIVUS, Inc.
MOUNTAIN VIEW, Calif., Aug. 1, 2013 (GLOBE NEWSWIRE) -- VIVUS, Inc. (Nasdaq:VVUS) today announced that it has entered into a Commercial Supply Agreement with Sanofi Chimie ("Sanofi"), a wholly owned...
VIVUS Board Selects Michael Astrue as Chairman and Tony Zook as CEO
22. Juli 2013 21:15 ET
|
VIVUS, Inc.
MOUNTAIN VIEW, Calif., July 22, 2013 (GLOBE NEWSWIRE) -- VIVUS, Inc. (Nasdaq:VVUS) ("VIVUS"), which recently began selling the obesity drug Qsymia® (phentermine and topiramate extended-release)...
VIVUS, First Manhattan and Sarissa Capital Announce Settlement Agreement
18. Juli 2013 23:15 ET
|
VIVUS, Inc.
Reconstituted Slate Will Include Six First Manhattan Nominees and Four VIVUS Nominees
Anthony Zook is Expected to Serve as New CEO and to be Appointed to the Board
Annual Meeting to be...
FMC Rejects Settlement Proposal From VIVUS
17. Juli 2013 05:30 ET
|
VIVUS, Inc.
VIVUS Proposal Included Leland Wilson, Chief Executive Officer, Offering to Retire
VIVUS Compromise Included Board Consisting of Four Nominees From Each Side and One Independent Investor...
VIVUS Identifies False and Misleading Statements Made by First Manhattan Co.
16. Juli 2013 18:34 ET
|
VIVUS, Inc.
FMC's "Win at all Costs" Campaign Infringes on Stockholders' Rights to Make Informed Voting Decisions
VIVUS Urges Stockholders to Vote FOR the Company's Nominees on the GOLD Proxy...
First Manhattan Co.'s False and Misleading Statements Reported to the U.S. Securities and Exchange Commission
14. Juli 2013 22:15 ET
|
VIVUS, Inc.
VIVUS Demands Immediate Corrective Disclosure by FMC
VIVUS to Adjourn Annual Meeting of Stockholders to Thursday, July 18, 2013
Urges Stockholders to Vote FOR the Company's Nominees on the GOLD...